BA
GEVA

BlackRock Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BlackRock Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-187,036
Closed -$18.2M – 3799
2015
Q1 		$18.2M Buy
187,036
+167,659
+865% +$17.8M 0.02% 588
2014
Q4 		$1.8M Buy
19,377
+3,123
+19% +$246K ﹤0.01% 1236
2014
Q3 		$1.12M Sell
16,254
-6,338
-28% -$454K ﹤0.01% 1375
2014
Q2 		$2.37M Sell
22,592
-2,336
-9% -$199K ﹤0.01% 1132
2014
Q1 		$2.07M Sell
24,928
-97,979
-80% -$9.06M ﹤0.01% 1169
2013
Q4 		$7.96M Sell
122,907
-26,859
-18% -$1.59M 0.01% 871
2013
Q3 		$9.49M Sell
149,766
-167,597
-53% -$8.25M 0.01% 804
2013
Q2 		$13.3M Buy
+317,363
New +$14.5M 0.01% 683

BlackRock Advisors's GEVA Position: Q2 2015 in Review

BlackRock Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 187,036 shares — an estimated $18.2M sold.

BlackRock Advisors first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $18.2M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • BlackRock Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • BlackRock Advisors sold 187,036 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $18.2M.
  • BlackRock Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • BlackRock Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $18.2M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BlackRock Advisors's 13F filing for Q2 2015, filed 7 Aug 2015.